Portfolio

Tubulis

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

Press releases

HTGF Investment Tubulis

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates Tubulis today announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug…
Read

Info & Contact

Address

Tubulis GmbH
Butenandtstraße 1
81377 Munich
Germany

In portfolio

17. Jul 2020